CRYSTAL STEPHENS: Open Payments
NPI 1154849529 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$508 in 32 payments from 9 companies in 2025. Trend: 2023 $270 · 2024 $343 · 2025 $508
Food & beverage: $508
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $246 |
| PFIZER INC. | 3 | $64 |
| AstraZeneca Pharmaceuticals LP | 3 | $51 |
| Novo Nordisk Inc | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Corcept Therapeutics | 1 | $26 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $21 |
| GlaxoSmithKline, LLC. | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
Products named: UBRELVY, QULIPTA, ELIQUIS, VRAYLAR, AUSTEDO XR, Korlym, RELISTOR, BREZTRI.
Industry payments across TX — which companies pay providers there.
